by ecmamerica | Dec 5, 2019 | Resources
This post was originally published on this siteSage Therapeutics’ key phase 3 trial in major depressive disorder has missed its primary endpoint. The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the...
by ecmamerica | Dec 5, 2019 | Resources
This post was originally published on this siteBarcelona-based medical device company Anaconda Biomed has raised €20m in a funding round, with plans to use the proceeds for clinical studies, regulatory submissions, product development and manufacturing scale-up....
by ecmamerica | Dec 5, 2019 | Resources
This post was originally published on this siteStanford Health Care recently opened its new state-of-the-art hospital in Palo Alto, California, US. With seven floors and 824,000 square feet, the US$2.1bn new Stanford Hospital doubles the size of its existing emergency...
by ecmamerica | Dec 5, 2019 | Resources
This post was originally published on this siteThe digital health technology company, TytoCare, has launched a handheld telemedicine device, called TytoHome, nationwide in the US through the retailer BestBuy. TytoHome is a telemedicine platform that allows a doctor to...
by ecmamerica | Dec 5, 2019 | Resources
This post was originally published on this siteA phase 3 trial of Aurinia Pharmaceuticals’ voclosporin in lupus nephritis has hit its primary endpoint, causing the company’s share price to double. The data tee Aurinia up to file for FDA approval next year...
